A comparison of DCD Heart Transplantation in Europe and the United States: A multi-centre, retrospective study.

Autores de IDIVAL

• 

  Francisco Jesús González Vílchez

  Autor

Autores ajenos al IDIVAL

• Louca, John O
• Ochsner, Marco
• Shah, Ashish
• Schlendorf, Kelly
• Lima, Brian
• Wang, Chen Chia
• Siddiqi, Hasan
• Irshad, Ali
• Schroder, Jacob
• Casalinova, Sarah
• Milano, Carmelo
• Khush, Kiran K
• Skoda, Anette
• Luikart, Helen
• Ashley, Euan
• Moazami, Nader
• James, Les
• Dar, Owais
• Konicoff, Mailen
• Urban, Marian
• Um, John
• Castleberry, Anthony
• Hoffman, Jordan R H
• Cain, Michael T
• Fetten, Katharina
• Meyer, Dan
• Xu, Addison
• Dominguez-Gil, Beatriz
• Royo-Villanova, Mario
• Garrido, Iris
• Canovas, Sergio J
• Brouckaert, Janne
• Vandendriessche, Katrien
• Rega, Filip
• Tchana-Sato, Vincent
• Berman, Marius
• Bae, James
• Asemota, Nicole
• Sinha, Sanjay
• Pettit, Stephen
• Messer, Simon
• Large, Stephen
• Bhagra, Sai
• ODDCAT collaborators

Unidades

• INVESTIGACIÓN CARDIOVASCULAR

Abstract

BACKGROUND: Donation after the circulatory determination of death (DCD) heart transplantation (HT) is becoming more widely adopted across the United States (US) and Europe. OBJECTIVE: This study compared donor and recipient demographics, intraoperative parameters and outcomes between DCD HT centres in Europe and the US that contributed to the Outcomes after DCD Cardiac Transplantation Database. METHODS: This was a retrospective observational study across 22 HT centres in Belgium, Spain, United Kingdom (UK) and US. All patients undergoing DCD HT at participating centres, from the start of each centre's DCD program through 01/01/2023 were included with censor date 01/01/2024. The primary outcome was 1-year survival. Secondary outcomes included severe primary graft dysfunction and incidence of acute cellular rejection. RESULTS: Data from 223 patients in Europe and 281 in the US were analysed. DCD donors in Europe were significantly older (37years vs 28 years;p<0.001). Recipients in Europe had inferior 1-year survival (86.6% vs 91.8%;p=0.043), but 1-month and 3-years survival were similar. 1-year survival in the direct procurement and preservation (DPP) cohort was significantly higher in the US group (91.2% vs 82.6%;p=0.02). In the thoraco-abdominal normothermic regional perfusion (taNRP) cohort 1-year survival was similar between Europe and the US. Recipients in Europe had higher use of mechanical circulatory-assist post-transplant (17.9% vs 11%;p=0.03). CONCLUSION: This study further confirms the safety and efficacy of DCD HT across centres in the US and Europe, despite important differences in donor and recipient demographics and clinical outcomes. Continued collection of international data may identify opportunities to improve outcomes.

Copyright © 2026 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Keywords

• DCD; Heart Transplant